Provided by Tiger Trade Technology Pte. Ltd.

WUXI XDC

71.650
+1.4502.07%
Volume:7.92M
Turnover:564.36M
Market Cap:90.71B
PE:54.83
High:72.400
Open:70.200
Low:69.100
Close:70.200
52wk High:85.500
52wk Low:43.500
Shares:1.27B
HK Float Shares:1.27B
Volume Ratio:1.00
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.307
ROE:17.05%
ROA:8.60%
PB:7.25
PE(LYR):54.83
PS:13.08

Loading ...

WuXi XDC files HKEX next-day return, issues 1,507,353 shares at HKD 1.8-7.5

Reuters
·
Apr 08

WuXi XDC grants 4,854,500 nil-cost restricted shares under 2024 scheme

Reuters
·
Apr 08

WuXi XDC Adds 0.84 Million Shares in March 2026 as Pre-IPO Options Are Exercised

Bulletin Express
·
Apr 08

Akari partners with WuXi XDC to accelerate PH1 ADC payload development, IND by 2026

Reuters
·
Apr 06

HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%

Tiger Newspress
·
Mar 27

HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.

Tiger Newspress
·
Mar 26

CLSA Raises Target Price for WUXI XDC to HK$80.9, Citing Improved Profit Visibility

Stock News
·
Mar 25

CICC Maintains Outperform Rating on WUXI XDC with HK$88.0 Target Price

Stock News
·
Mar 25

WuXi XDC Cayman (SEHK:2268) Margin Slip Tests Bullish Growth Narrative After FY 2025 Earnings

Simply Wall St.
·
Mar 24

Morgan Stanley Assigns "Overweight" Rating to WUXI XDC (02268) with HK$86 Price Target

Stock News
·
Mar 24

From Enabler to Innovator: WUXI XDC's Evolution and Value Transformation in the CRDMO Sector

Stock News
·
Mar 24

Pharmaceutical Sector Leads Hong Kong Market Rebound with Strong ETF Performance

Deep News
·
Mar 24

HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%

Tiger Newspress
·
Mar 24

Stock Track | WUXI XDC Soars 5.22% Intraday on Strong Fiscal Year Results

Stock Track
·
Mar 24

BRIEF-Wuxi Xdc Cayman Inc Posts FY Adjusted Net Profit Attributable RMB1.56 Billion

Reuters
·
Mar 23

WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate Crdmo

THOMSON REUTERS
·
Mar 23

WUXI XDC (02268) Maintains Strong 2025 Performance, Strengthens Leadership Through Global Expansion and Technology

Stock News
·
Mar 23

WuXi XDC posts 46.7% revenue jump to RMB 5.94 bn in 2025, sets RMB 8 bn capex plan to deepen global bioconjugate CDMO leadership

Bulletin Express
·
Mar 23

WUXI XDC Reports Double-Digit Growth in 2025 Revenue and Net Profit

Stock News
·
Mar 23

Wuxi XDC FY2025 gross profit jumps 72.5% to RMB 2.14 billion

Reuters
·
Mar 23